Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.95 USD | -1.97% | +17.30% | +143.87% |
Feb. 12 | North American Morning Briefing : Stock Futures -2- | DJ |
Feb. 09 | Jefferies Upgrades Inotiv to Buy Rating From Hold, Adjusts Price Target to $11.50 From $3 | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+143.87% | 231M | D+ | ||
+9.72% | 46.21B | B | ||
+34.94% | 40.04B | A | ||
+4.84% | 39.92B | B- | ||
-9.43% | 28.33B | C | ||
+17.47% | 27.43B | B- | ||
-22.99% | 18.57B | B | ||
+10.88% | 13.46B | C+ | ||
+27.53% | 12.02B | C+ | ||
-6.84% | 11.3B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Inotiv, Inc. - Nasdaq
- Ratings Inotiv, Inc.